MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory diseaseData expected to inform immune modulation, treatment ...

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

Presenter: Terese C. Hammond, MD; Program Director of Pulmonary and Critical Care, Kaweah Health Medical Center; Head of Inflammatory and Pulmonary Diseases, MiNK Therapeutics ...

MiNK outlines initial ARDS Phase II data in H2 2026 while extending runway through 2026

Dr. Jennifer Buell (President, CEO & Director) reiterated MiNK’s differentiation as “an off the shelf” allogeneic iNKT platform that is “administered without lymphodepletion, without HLA matching,” ...

MiNK Therapeutics Q4 Earnings Call Highlights

MiNK Therapeutics (NASDAQ:INKT) outlined progress across its allogeneic invariant natural killer T-cell (iNKT) platform ...
Forbes

Denmark Begins Exhuming Millions Of Mink Killed To Contain Covid

Denmark began the unpleasant task of exhuming millions of mink Thursday to safeguard nearby waters from contamination by poorly-dug graves of mink culled last year to prevent the spread of mutant ...
The Caledonian-Record

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance ...